Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

Phase 2

Completed

• Conditions: Hyperhidrosis
• Interventions: Drug: Dose 1 of glycopyrrolate, 2.0% QD; Drug: Dose 2 of glycopyrrolate, 3.0% QD; Drug: Dose 1 of glycopyrronium, 2.5% QD; Other: Vehicle; Drug: Dose 2 of glycopyrronium, 3.75% QD

• Registration Number: NCT02129660
• Lead Sponsor: Journey Medical Corporation

Brief Summary

The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks followed by a 2-week post-dose period.

Detailed Description

This is a randomized, double-blind, vehicle controlled, parallel group, comparator study designed to assess the safety, efficacy and pharmacokinetics of two doses of glycopyrrolate compared to two doses of glycopyrronium compared to vehicle, 5 treatment arms.

Efficacy will be assessed through gravimetric assessment of sweat production using Patient Reported Outcome and the Hyperhidrosis Disease Severity Score (HDSS).

Safety will be assessed through adverse events, local skin responses, serum chemistry and hematology laboratory testing, ECGs, physical examination and vital signs.

PK blood samples will be taken study subjects.

Study Timeline

• Study Start: 2014-04
• Study First Submitted: 2014-04-30
• Study First Submitted QC: 2014-04-30
• Study First Posted: 2014-05-02
• Primary Completion: 2015-01
• Study Completion: 2015-01
• Disposition First Submitted: 2015-10-22
• Disposition First Submitted QC: 2015-10-22
• Disposition First Posted: 2015-11-13
• Results First Submitted: 2018-07-17
• Results First Submitted QC: 2018-08-28
• Results First Posted: 2018-09-04
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-23
• Last Update Posted: 2021-08-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

• Male or female, 18 years of age or older.
• Primary, axillary hyperhidrosis of at least 6 months duration.
• Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.
• For each axilla, a baseline gravimetric measurement of sweat production of at least 50 mg over 5 minutes, while at rest, at room temperature.
• Male or non-pregnant, non-lactating females.

Read More

Exclusion Criteria

• Current pregnancy or lactation.
• Prior surgical procedure for hyperhidrosis.
• Any prior axillary treatment with an anti-hyperhidrosis medical device
• Any prior treatment with an investigational drug within 4 weeks prior to Baseline/Day 1 or within 5 elimination half lives of the active agent, whichever is longer or 6 weeks if the elimination half life is not known. Experimental devices are excluded without the approval of the Medical Monitor.
• Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within 1 year of Baseline/Day 1.
• Subjects with clinically significant abnormalities in laboratory values.
• Subjects with a positive Hepatitis or HIV.Hepatitis B surface antibody positive is allowed only if the subject has a history of having received Hepatitis B vaccination and there are no clinically significant abnormalities in screening liver function tests.
• Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists thought to relieve antidepressant-induced hyperhidrosis, within one month prior to Baseline/Day 1.
• Treatment with psychotherapeutic medications for less than 4 months prior to Baseline/Day 1.
• Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine), or beta-blockers within 4 weeks of the baseline visit
• Prior treatment with axillary iontophoresis within 4 weeks of Baseline/Day 1.
• Any previous IV or oral treatment with the study drug.
• Prior treatment with the topical study drug in a previous trial.
• Axillary use of nonprescription or prescription antiperspirants within 2 weeks of study enrollment.
• Presence of a condition, within 10 years of enrollment, that may cause secondary hyperhidrosis
• Menopausal women who have had symptoms of menopause such as sweating or flushing within 3 years of the study may not be enrolled.
• Known history of Sjögren's syndrome or Sicca syndrome.
• History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness.
• Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy.
• Abnormal findings on screening ECG deemed clinically significant by the Investigator.
• History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter. History of other supraventricular tachycardia

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dose 1 of glycopyrrolate, 2.0% QD	Dose 1 of glycopyrrolate, 2.0% QD	glycopyrrolate Topical Wipes
Dose 2 of glycopyrrolate, 3.0% QD	Dose 2 of glycopyrrolate, 3.0% QD	glycopyrrolate Topical Wipes
Dose 1 of glycopyrronium, 2.5% QD	Dose 1 of glycopyrronium, 2.5% QD	glycopyrronium Topical Wipes
Vehicle	Vehicle	Vehicle Topical Wipes
Dose 2 of glycopyrronium, 3.75% QD	Dose 2 of glycopyrronium, 3.75% QD	glycopyrronium Topical Wipes

Primary Outcome Measures

Name	Time	Method
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 4	Baseline - Week 4
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 6	Baseline - Week 6
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 6	Baseline - Week 6
Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4	Baseline - Week 4/ET	HDSS is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.; 1 (Best), 2, 3, 4 (Worst)
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 4	Baseline - Week 4	Subjects are acclimated to the environment for 30 minutes. Dry gauze is weighed. The dry gauze is then applied to the subject's axilla with the arm down by the subject's side or on their lap during the 5-minute period of sweat production. The gauze with the sweat is then weighed. The difference between the Weight of the gauze with sweat and the dry gauze is the gravimetric sweat measurement in mg/5min.

Secondary Outcome Measures

Name	Time	Method
Percentage of Subjects Who Had at Least 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 4	Baseline - Week 4
Percentage of Subjects Who Had at Least 50% Reduction in Gravimetrically Measured Sweat Production From Baseline at Week 6	Baseline - Week 6

Trial Locations

Locations (15)

Kenneth R. Beer MD; 🇺🇸 West Palm Beach, Florida, United States

Shideler Clinical Research Center; 🇺🇸 Carmel, Indiana, United States

Dermatology Research Center, Inc.; 🇺🇸 Salt Lake City, Utah, United States

California Dermatology & Clinical Research Institute; 🇺🇸 Encinitas, California, United States

Center For Dermatology Clinical Research; 🇺🇸 Fremont, California, United States

Rivergate Dermatology Clinical Research Center, PLLC; 🇺🇸 Goodlettsville, Tennessee, United States

Olympian Clinical Research; 🇺🇸 Tampa, Florida, United States

Haber Dermatology and Cosmetic Surgery; 🇺🇸 Beachwood, Ohio, United States

Virginia Clinical Research, Inc.; 🇺🇸 Norfolk, Virginia, United States

Saint Louis University Dermatology; 🇺🇸 Saint Louis, Missouri, United States

DermResearch, Inc; 🇺🇸 Austin, Texas, United States

Dermatology Associates; 🇺🇸 Seattle, Washington, United States

Women's Clinical Research Center; 🇺🇸 Seattle, Washington, United States

Innovaderm Research Inc.; 🇨🇦 Montreal, Canada

Premier Clinical Research; 🇺🇸 Spokane, Washington, United States